SIRT5 desuccinylates the K413 of isocitrate dehydrogenase 2 (IDH2) and upregulates its activity, leading to increased ccRCC cell viability, increased ROS production and dysfunction of mitochondrial, attenuating the anticancer efficacy of sunitinib [103]. Here, SIRT5 is linked to nonpapillary renal cell carcinoma.